While Rocket Lab USA’s operational performance continues to break records, its share price tells a different story. The company is preparing for its 19th mission of the year, yet investor sentiment has cooled significantly following a key schedule change for its next-generation rocket.
Share Price Correction Contrasts Operational Momentum
The equity has undergone a notable correction, trading approximately 30% below its all-time high reached in October. This market hesitation persists even as the company’s launch cadence hits unprecedented levels. The imminent “RAISE and Shine” mission for Japan’s JAXA space agency from New Zealand will mark the 19th successful launch this year, maintaining a flawless 100% success rate. This pace has already surpassed last year’s record, putting Rocket Lab on track to potentially exceed 20 launches before year-end.
Neutron Delay: The Core of Investor Concern
The primary catalyst for November’s share price decline is the revised timeline for the ambitious Neutron project. The inaugural flight of this new, reusable launch vehicle has been pushed from late 2025 to the first quarter of 2026.
This postponement carries substantial weight for the long-term investment thesis. Neutron represents a fundamental leap in capability, designed to carry a payload of 13,000 kilograms—roughly forty times the capacity of the current Electron rocket. Successfully deploying Neutron would position Rocket Lab as a direct competitor to SpaceX’s Falcon 9, unlocking access to significantly larger revenue streams in the commercial launch market.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
Strong Fundamentals Provide a Counterbalance
Despite the schedule setback, the company’s latest financial results offer reassurance. Third-quarter revenue surged 48% to a record high exceeding $155 million. The gross margin also expanded, reaching 37%. Furthermore, Rocket Lab maintains a solid financial position with a liquidity reserve of over $1 billion.
This fundamental strength has led several market analysts to maintain a constructive view. Researchers at Stifel Nicolaus described the adjusted Neutron schedule as “more realistic” and subsequently raised their price target to $75. Morgan Stanley also downplayed the severity of the delay, noting that the company’s priority appears to be mission success over pure development speed.
The Path Forward: A Pivotal 2026 Debut
All attention now turns to early 2026. This period is expected to see the Neutron rocket arrive at the launch site, complete qualification testing, and achieve its first liftoff. The commercialization of this new rocket generation is viewed as the critical lever for future profitability, especially considering the company’s cash burn of approximately $232 million over the preceding twelve months.
The coming quarters will thus serve as a defining period, testing investor patience against the backdrop of ongoing operational excellence in Rocket Lab’s core Electron launch business.
Ad
Rocket Lab USA Stock: Buy or Sell?! New Rocket Lab USA Analysis from December 7 delivers the answer:
The latest Rocket Lab USA figures speak for themselves: Urgent action needed for Rocket Lab USA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 7.
Rocket Lab USA: Buy or sell? Read more here...
